These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 6301258

  • 1. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
    Awwad HK, Barsoum M, El Merzabani M, Omar S, El Badawy S, Ezzat S, El Baki HA, Zaki A.
    Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, Reiter E.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):374-87. PubMed ID: 15380569
    [Abstract] [Full Text] [Related]

  • 3. Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
    Ishii K, Tashiro M, Hosono M, Fukuda H, Takada Y, Kondo S, Inoue Y, Iguchi H, Kusuki M, Yamane H.
    Acta Otolaryngol Suppl; 2004 Oct 01; (554):62-6. PubMed ID: 15513514
    [Abstract] [Full Text] [Related]

  • 4. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India.
    Ghoshal S, Goda JS, Mallick I, Kehwar TS, Sharma SC.
    Clin Oncol (R Coll Radiol); 2008 Apr 01; 20(3):212-20. PubMed ID: 18343310
    [Abstract] [Full Text] [Related]

  • 5. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
    Br J Radiol; 1984 Jul 01; 57(679):585-95. PubMed ID: 6329395
    [Abstract] [Full Text] [Related]

  • 6. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
    Van den Bogaert W, van der Schueren E, Horiot JC, Chaplain G, Arcangeli G, Gonzalez D, Svoboda V.
    Int J Radiat Oncol Biol Phys; 1982 Oct 01; 8(10):1649-55. PubMed ID: 7153077
    [Abstract] [Full Text] [Related]

  • 7. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience.
    Zamboglou N, Schnabel T, Kolotas C, Achterrath W, Strehl H, Dalhäuser S, Vogt HG, Lenaz L, Schmitt G.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 12):45-53. PubMed ID: 7992066
    [Abstract] [Full Text] [Related]

  • 8. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, Miller L, Weinstein GS, Weber RS.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):72-7. PubMed ID: 15093901
    [Abstract] [Full Text] [Related]

  • 9. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer.
    Zouhair A, Azria D, Pasche P, Stupp R, Chevalier J, Betz M, Mirimanoff RO, Ozsahin M.
    Radiother Oncol; 2004 Feb 01; 70(2):183-8. PubMed ID: 15028406
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.
    Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, Sygula M, Wygoda A.
    Int J Radiat Oncol Biol Phys; 2006 Nov 01; 66(3):706-13. PubMed ID: 17011446
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N, Kitahara S, Tamura E, Tanabe T, Nakanoboh M, Kawada M, Shirasaka T.
    Gan To Kagaku Ryoho; 2000 May 01; 27 Suppl 2():592-9. PubMed ID: 10895216
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P, Putnik K, Kreimeyer T, Sprague LD, Koelbl O, Schäfer C.
    BMC Cancer; 2006 Dec 07; 6():279. PubMed ID: 17150114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.